The Journal of Bone and Joint Surgery (American) 84:49-57 (2002)
© 2002 The Journal of Bone and Joint Surgery, Inc.
Pathologic Fracture in Osteosarcoma
Prognostic Importance and Treatment Implications
Sean P. Scully, MD, PhD,
Michelle A. Ghert, MD,
David Zurakowski, PhD,
Roby C. Thompson, Jr.MD and
Mark C. Gebhardt, MD in Representation of the Musculoskeletal Tumor Society
Investigation performed at the Musculoskeletal Oncology Division,
Department of Orthopaedic Surgery, Duke University Medical Center,
Durham, North Carolina; Massachusetts General Hospital, Boston,
Massachusetts; Oregon Health Sciences University, Portland, Oregon;
Primary Childrens Hospital, Salt Lake City, Utah; University
of California at Los Angeles, Los Angeles, California; University
of Florida, Gainesville, Florida; University of Miami Medical Center, Miami,
Florida; and University of Minnesota, Minneapolis, Minnesota
Sean P. Scully, MD, PhD
Department of Orthopaedic Surgery, Mayo Clinic, 200 First Street
S.W., Rochester, MN 55905. E-mail address: scully.sean{at}mayo.edu
Michelle A. Ghert, MD
Division of Orthopaedics, Department of Surgery, Duke University
Medical Center, Durham, NC 27710
David Zurakowski, PhD
Departments of Orthopaedic Surgery and Biostatistics, Childrens
Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA
02115
Roby C. Thompson Jr., MD
Department of Orthopaedic Surgery, University of Minnesota Medical
Center, 420 Delaware Street S.E., Minneapolis, MN 55455
Mark C. Gebhardt, MD
Department of Orthopaedic Surgery, Massachusetts General Hospital,
32 Fruit Street, Boston, MA 02114
The authors did not receive grants or outside funding in support
of their research or preparation of this manuscript. They did not
receive payments or other benefits or a commitment or agreement
to provide such benefits from a commercial entity. No commercial
entity paid or directed, or agreed to pay or direct, any benefits
to any research fund, foundation, educational institution, or other
charitable or nonprofit organization with which the authors are
affiliated or associated.
A commentary is available with the electronic versions of this article,
on our web site (www.jbjs.org) and on our quarterly CD-ROM (call
our subscription department, at 781-449-9780, to order the CD-ROM).
Background: The presence of a pathologic fracture
in an osteosarcoma has been considered a poor prognostic factor
and an indication for immediate amputation. The purpose of the present
study was to determine, in the current era of neoadjuvant chemotherapy, whether
a pathologic fracture in an osteosarcoma has prognostic importance
and whether limb salvage can be safely performed in such patients
without compromising clinical outcome.
Methods: In a cooperative effort of the Musculoskeletal
Tumor Society, members from eight institutions provided retrospective
data on fifty-two patients with osteosarcoma who had a pathologic fracture
and on fifty-five patients with osteosarcoma who had not had a pathologic
fracture and had been followed for at least two years or until disease
recurrence, metastasis, or death. The two groups were matched for
patient age and tumor location. Outcomes examined were survival
and local recurrence. A subgroup analysis was performed to assess
differences in outcome within the group with the pathologic fracture.
Results: The five-year estimated survival rates
were 55% for the group with a pathologic fracture and 77% for
the group without a fracture (p = 0.02). The rate of survival
without a local recurrence at five years was 75% for the
group with a fracture and 96% for the group without a fracture
(p = 0.007). In the group with a fracture, seven (23%)
of the thirty patients managed with limb salvage and four (18%)
of the twenty-two managed with an amputation had a local recurrence
(p = 0.75). Eleven (37%) of the thirty patients
with a fracture who were managed with limb salvage and ten (45%)
of the twenty-two patients with a fracture who were managed with
an amputation died of the disease (p = 0.50). Five patients
underwent open reduction and internal fixation followed by limb-salvage
surgery. Two of them had a local recurrence and died at an average
of eight months postoperatively. The remaining three patients were alive
at an average of 6.1 years postoperatively. Local disease control
and the survival of these patients were not significantly different
from those for the thirty-three patients who were treated with nonoperative
immobilization of the fracture followed by limb-salvage surgery.
Conclusions: Patients with osteosarcoma who present
with a pathologic fracture or sustain one during preoperative chemotherapy have
an increased risk of local recurrence and a decreased rate of survival
compared with patients who have not sustained a pathologic fracture.
The performance of a limb-salvage procedure in carefully selected
patients with a pathologic fracture does not significantly increase
the risk of local recurrence or death. Factors predictive of improved
outcome, such as the response to chemotherapy and union of the fracture,
should be taken into account when limb salvage is being considered.

CiteULike Connotea Del.icio.us Facebook Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. J. Messerschmitt, R. M. Garcia, F. W. Abdul-Karim, E. M. Greenfield, and P. J. Getty
Osteosarcoma
J. Am. Acad. Ortho. Surg.,
August 1, 2009;
17(8):
515 - 527.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Discepola, T. I. Powell, and A. Nahal
Best Cases from the AFIP: Telangiectatic Osteosarcoma: Radiologic and Pathologic Findings1
RadioGraphics,
March 1, 2009;
29(2):
380 - 383.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Kocher and J. F. Sarwark
What's New in Pediatric Orthopaedics
J. Bone Joint Surg. Am.,
June 1, 2004;
86(6):
1337 - 1346.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Kocher and D. Zurakowski
Clinical Epidemiology and Biostatistics: A Primer for Orthopaedic Surgeons
J. Bone Joint Surg. Am.,
March 1, 2004;
86(3):
607 - 620.
[Full Text]
[PDF]
|
 |
|
|